KR20170008327A - 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질 - Google Patents

정신적 질환의 치료 용도를 위한 일로페리돈 대사물질 Download PDF

Info

Publication number
KR20170008327A
KR20170008327A KR1020177001093A KR20177001093A KR20170008327A KR 20170008327 A KR20170008327 A KR 20170008327A KR 1020177001093 A KR1020177001093 A KR 1020177001093A KR 20177001093 A KR20177001093 A KR 20177001093A KR 20170008327 A KR20170008327 A KR 20170008327A
Authority
KR
South Korea
Prior art keywords
day
twice
once
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177001093A
Other languages
English (en)
Korean (ko)
Inventor
디팍 파드케
컬트 디. 울프강
미헬 에이치. 폴리메로파울로스
존 요셉 피니
건터 버즈닉스
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170008327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Publication of KR20170008327A publication Critical patent/KR20170008327A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177001093A 2012-03-14 2013-03-14 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질 Ceased KR20170008327A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610664P 2012-03-14 2012-03-14
US61/610,664 2012-03-14
PCT/US2013/031413 WO2013138602A1 (en) 2012-03-14 2013-03-14 An iloperidone metabolite for use in the treatment of psychiatric disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147026434A Division KR20140121487A (ko) 2012-03-14 2013-03-14 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질

Publications (1)

Publication Number Publication Date
KR20170008327A true KR20170008327A (ko) 2017-01-23

Family

ID=48407766

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177001093A Ceased KR20170008327A (ko) 2012-03-14 2013-03-14 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질
KR1020147026434A Ceased KR20140121487A (ko) 2012-03-14 2013-03-14 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147026434A Ceased KR20140121487A (ko) 2012-03-14 2013-03-14 정신적 질환의 치료 용도를 위한 일로페리돈 대사물질

Country Status (17)

Country Link
US (3) US10874659B2 (enExample)
EP (2) EP3345603B1 (enExample)
JP (5) JP2015510893A (enExample)
KR (2) KR20170008327A (enExample)
CN (2) CN108938632A (enExample)
AU (2) AU2013232014B2 (enExample)
BR (1) BR112014022687A8 (enExample)
CA (1) CA2865845C (enExample)
CL (1) CL2014002430A1 (enExample)
CO (1) CO7091183A2 (enExample)
ES (2) ES2773711T3 (enExample)
IL (1) IL234412B (enExample)
IN (1) IN2014DN08495A (enExample)
MX (1) MX374067B (enExample)
RU (1) RU2651710C2 (enExample)
WO (1) WO2013138602A1 (enExample)
ZA (1) ZA201406369B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2870498T3 (es) 2015-02-17 2021-10-27 Vanda Pharmaceuticals Inc Iloperidona para el tratamiento de esquizofrenia
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
JP2026504721A (ja) 2022-12-19 2026-02-09 バンダ・ファーマシューティカルズ・インコーポレイテッド 双極ｉ型障害及び統合失調症の治療のためのイロペリドンの投与レジメン
WO2024249952A1 (en) * 2023-06-02 2024-12-05 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
DK2305656T3 (da) 2001-08-31 2013-02-11 Novartis Ag Optiske isomerer of en iloperidonmetabolit
PT1458888E (pt) 2001-12-10 2011-06-01 Novartis Ag Métodos para tratar a psicose e a esquizofrenia baseados em polimorfismos no gene do cntf
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
AU2007253684A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
EP2134873B1 (en) 2007-03-29 2015-05-06 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
EP2198048A2 (en) 2007-09-10 2010-06-23 Vanda Pharmaceuticals Inc. Prediction of qt prolongation based on snp genotype
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
CA2757723C (en) 2009-04-06 2018-07-24 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
HUE037724T2 (hu) 2009-04-06 2018-09-28 Vanda Pharmaceuticals Inc Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésre
EP2417266B1 (en) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US9072742B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
CA2760474C (en) 2009-05-15 2020-08-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype

Also Published As

Publication number Publication date
JP2021001221A (ja) 2021-01-07
ES2677474T3 (es) 2018-08-02
BR112014022687A2 (pt) 2017-06-20
JP2017061506A (ja) 2017-03-30
US20210015809A1 (en) 2021-01-21
US20150045390A1 (en) 2015-02-12
EP2825167B1 (en) 2018-05-09
KR20140121487A (ko) 2014-10-15
EP3345603B1 (en) 2019-12-18
JP2015510893A (ja) 2015-04-13
CN104203240A (zh) 2014-12-10
IN2014DN08495A (enExample) 2015-05-08
JP2023022243A (ja) 2023-02-14
CO7091183A2 (es) 2014-10-21
AU2013232014A1 (en) 2014-09-18
US10874659B2 (en) 2020-12-29
AU2016203591A1 (en) 2016-06-16
ES2773711T3 (es) 2020-07-14
JP2018203774A (ja) 2018-12-27
IL234412B (en) 2018-04-30
CN108938632A (zh) 2018-12-07
WO2013138602A1 (en) 2013-09-19
ZA201406369B (en) 2023-10-25
RU2651710C2 (ru) 2018-04-23
EP3345603A1 (en) 2018-07-11
AU2016203591B2 (en) 2018-03-08
RU2014141112A (ru) 2016-05-10
US20240016791A1 (en) 2024-01-18
CA2865845A1 (en) 2013-09-19
JP7151029B2 (ja) 2022-10-12
CL2014002430A1 (es) 2015-04-17
MX2014010989A (es) 2015-03-10
MX374067B (es) 2020-07-30
CA2865845C (en) 2020-02-18
BR112014022687A8 (pt) 2021-07-06
AU2013232014B2 (en) 2016-06-16
EP2825167A1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
TWI776407B (zh) 激動劑形成之調配物及使用其之方法
US20090023712A1 (en) Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
JP2023022243A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
US20060258640A1 (en) Use of Flibanserin in the treatment of chronic pain
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
US9839627B2 (en) Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
CA2684174C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
MXPA02003452A (es) Tratamiento de combinacion de esclerosis multiple (em), otras condiciones de desmielinacion y neuropatia periferica, especialmente neuropatias dolorosas y neuropatia diabetica.
JP2020502106A (ja) 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用
WO2018102824A1 (en) Methods for treating neurodegenerative disease
HK1250490B (en) Iloperidone metabolite for use in the treatment of psychiatric disorders
HK1250490A1 (en) Iloperidone metabolite for use in the treatment of psychiatric disorders
WO2024059659A1 (en) Cycloalkyl carboxylic acid derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
JP2019524794A (ja) ヒスタミン−３受容体インバースアゴニストとアセチルコリンエステラーゼ阻害剤との組合せ
JP2005513149A (ja) α−グルコシダーゼ阻害剤及び４−オキソブタン酸を含む薬剤組成物並びにその糖尿病治療への使用
JP2018035086A (ja) 低活動膀胱の予防及び／又は治療薬

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170113

Application number text: 1020147026434

Filing date: 20140922

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180313

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180406

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180406

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20181226

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180806

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180313

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190402

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190327

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20181226

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180806

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180406

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180313

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20190702

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190402

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20181226

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20201123

Appeal identifier: 2019101002222

Request date: 20190702

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101002222; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20190702

Effective date: 20201123

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20201124

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20190702

Decision date: 20201123

Appeal identifier: 2019101002222

PJ2001 Appeal

Patent event date: 20201124

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20220120

Appeal identifier: 2021201001349

Request date: 20210120

PJ1302 Judgment (patent court)

Patent event date: 20220120

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20210120

Decision date: 20220120

Appeal identifier: 2021201001349

Appeal kind category: Appeal against decision to decline refusal